Saturday 17 October 2026
Export ATNM’s income statement to Excel — free account
Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
1.13
0.07
+6.60%
Follow ATNM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
2.72 | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.88 | — | — | 277.30 | |
P/FCF ratio |
0.00 | — | — | 0.00 | |
P/Operating CF |
(5.94) | — | — | (7.89) | |
P/B ratio |
1.02 | — | — | 3.62 | |
Price to Tangible BV |
1.02 | — | — | 3.62 | |
EV/Sales |
(0.16) | — | — | (19.31) | |
EV/EBITDA |
0.00 | — | — | 0.10 | |
EV/Operating CF |
0.25 | — | — | 0.14 | |
EV/FCF |
0.25 | — | — | 0.14 | |
Quick Ratio |
3.94 | 5.73 | 6.02 | 7.81 | |
Current Ratio |
4.08 | 5.89 | 6.20 | 7.96 | |
Net Debt/EBITDA |
(1.31) | 7.41 | 7.73 | 9.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.68 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.19) | 1.06 | 0.89 | 1.23 | |
Capex/Depreciation |
(1.98) | (0.01) | (0.50) | 0.00 | |
Research and Development Expense of Revenue |
15.36% | 0.00% | 0.00% | 4,720.00% | |
Selling, General and Administrative Expense of Revenue |
5.88% | 0.00% | 0.00% | 1,704.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.34% | 0.00% | 0.00% | 121.11% | |
Graham Net Nets |
0.91 | — | — | 0.24 | |
Graham Number |
2.80 | — | — | 0.00 | |
Earnings Yield |
36.73% | — | — | (68.75%) | |
Free Cash Flow Yield |
(75.55%) | — | — | (50.19%) | |
Revenue per Share |
1.11 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.19) | (0.17) | (0.20) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.19) | (0.17) | (0.20) | |
Cash per Share |
1.16 | 1.35 | 1.54 | 1.71 | |
Shareholders Equity per Share |
0.97 | 0.07 | 0.25 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 0.07 | 0.25 | 0.44 | |
Free Cash Flow |
(5.66) | (5.87) | (5.39) | (6.32) | |
Working Capital |
28.48 | 35.91 | 41.41 | 47.53 | |
Capital Expenditures |
(0.48) | 0.00 | (0.10) | — | |
Net Current Asset Value |
27.89 | 0.13 | 5.44 | 12.00 | |
EV/EBIT |
0.00 | — | — | 0.09 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
3.22 | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
8.11 | 6.57 | 7.41 | 6.71 | |
Average Assets |
51.59 | 57.04 | 64.34 | 69.13 | |
Average Common Equity |
24.66 | 14.00 | 20.30 | 26.00 |
Columns are period end dates